| DC47368 |
ZXH-4-130
|
ZXH-4-130 is a highly potent and selective degrader of CRBN. ZXH-4-130 is a CRBN-VHL compound (hetero-PROTAC). |
| DC47367 |
MS83
|
MS83 is a proof-of-concept PROTAC by linking the KEAP1 ligand to a BRD4/3/2 binder. |
| DC47366 |
CFT-2718
|
CFT-2718 is a new BRD4-targeting degrader (PROTAC) with enhanced catalytic activity and in vivo properties. |
| DC47365 |
di-Ellipticine-RIBOTAC
|
di-Ellipticine-RIBOTAC is a dual-function small molecule that reduces c9ALS/FTD r(G4C2) repeat expansion in vitro and in vivo amyotrophic lateral sclerosis (ALS ) models. |
| DC47364 |
ZXH-4-137
|
ZXH-4-137 is a potent and selective CRBN degrader (PROTAC). |
| DC47363 |
PROTAC CDK9 degrader-4
|
PROTAC CDK9 degrader-4 is a highly potent and efficacious CDK9 degrader for targeting transcription regulation. |
| DC47362 |
MS21
|
MS21, a novel degrader of AKT, selectively inhibits the growth of PI3K/PTEN pathway-mutant cancers with wild-type KRAS and BRAF. |
| DC47360 |
MS4322
|
MS4322 is a first-in-class PRMT5 degrader and a valuable chemical tool for exploring the PRMT5 functions in health and disease. |
| DC47265 |
ARD-61
|
ARD-61 is a highly potent, effective and specific PROTAC androgen receptor (AR) degrader. ARD-61 potently and effectively induces AR and progesterone receptors (PR) degradation in AR+ cancer cell lines. ARD-61 induces apoptosis and effectively induces tumor growth inhibition in the MDA-MB-453 xenograft model in mice. |
| DC47218 |
PROTAC CBP/P300 Degrader-1
|
PROTAC CBP/P300 Degrader-1 is a potent PROTAC CBP/P300 degrader. PROTAC CBP/P300 Degrader-1 potently inhibited cell viability of multiple cancer cell lines. |
